









Markets
/
Stocks
/
nasdaq-oabi
/

OmniAb Inc

OABI

1.700USD

+0.050+3.03%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

244.72MMarket Cap

LossP/E TTM



OmniAb Inc

1.700

+0.050+3.03%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of OmniAb Inc

Currency: USD Updated: 2026-02-06

Key Insights

OmniAb Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 124 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.33.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

OmniAb Inc's Score

Industry at a Glance

Industry Ranking

124 / 392

Overall Ranking

261 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

OmniAb Inc Highlights

StrengthsRisks

OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.

Growing

The company is in a growing phase, with the latest annual income totaling USD 26.39M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 26.39M.

Overvalued

The company’s latest PE is -2.89, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 79.79M shares, decreasing 21.46% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 95.33K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.18.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

7.333

Target Price

+344.44%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of OmniAb Inc is 5.83, ranking 320 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 2.24M, representing a year-over-year decrease of 46.33%, while its net profit experienced a year-over-year decrease of 0.93%.

Score

Industry at a Glance

Previous score

5.83

Change



Financials

6.70

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.10

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.45

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

OmniAb Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of OmniAb Inc is 7.14, ranking 164 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.89, which is -26.67% below the recent high of -2.12 and -790.50% above the recent low of -25.72.

Score

Industry at a Glance

Previous score

7.14

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 124/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of OmniAb Inc is 8.57, ranking 96 out of 392 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 11.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.57

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

7.333

Target Price

+344.44%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

OmniAb Inc

OABI

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of OmniAb Inc is 6.37, ranking 259 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.99 and the support level at 1.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.19

Change

0.18

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.059

Sell

RSI(14)

36.041

Neutral

STOCH(KDJ)(9,3,3)

13.283

Oversold

ATR(14)

0.118

High Vlolatility

CCI(14)

-122.631

Sell

Williams %R

86.022

Oversold

TRIX(12,20)

-0.311

Sell

StochRSI(14)

65.341

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.728

Sell

MA10

1.808

Sell

MA20

1.873

Sell

MA50

1.913

Sell

MA100

1.758

Sell

MA200

1.745

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of OmniAb Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 55.43%, representing a quarter-over-quarter increase of 12.79%. The largest institutional shareholder is The Vanguard, holding a total of 5.63M shares, representing 3.91% of shares outstanding, with 7.70% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Avista Capital Holdings, LP

15.82M

Whitefort Capital Management, LP

14.22M

+38.90%

Ash X LP

8.27M

+52.77%

BlackRock Institutional Trust Company, N.A.

6.30M

-0.52%

The Vanguard Group, Inc.

Star Investors

5.15M

-2.28%

Foehr (Matthew W)

4.35M

+0.30%

Cadian Capital Management LP

3.68M

Higgins (John L)

2.93M

+2.71%

Woodline Partners LP

2.86M

Dimensional Fund Advisors, L.P.

2.55M

-12.54%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of OmniAb Inc is 2.89, ranking 188 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.16. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.